PALM BEACH, Fla., April 29, 2021 /PRNewswire/ — The worldwide explosion of the recreational and medical cannabis markets, and submarkets, appears that it will continue for years to come.
“We are optimistic about the trend in Europe of governments following Canada’s lead in the legalization of cannabis,” said Paul Pedersen, CEO of Nextleaf Solutions.
According to a report by international cannabis research firm Brightfield Group, domestic cultivation and pressure on Europe’s healthcare system to allow general practitioners to prescribe cannabis as medicine, will result in a compound annual growth rate of 98% from 2020-2025.
This issued European patent pertains to a proprietary closed loop chilled solvent feed apparatus for post-extraction cannabinoid processing, and mirrors a patent previously granted by the United States Patent and Trademark Office and the Canadian Intellectual Property Office.
According to data from Prohibition Partners, medical cannabis imports to Germany grew 37% in 2020.
The change was the result of the European Union’s high court declaration in November 2020 that CBD derived from hemp was not a narcotic under an international drug treaty and would be subject to EU law on the free movement of goods among EU members.
“Through this groundbreaking partnership, we will leverage Southern Glazer’s established distribution network to bring our CBD beverage portfolio to retailers and consumers across the U.S.
GW Pharmaceuticals plc as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older.
“This is an exciting moment for patients, and their families, who are affected by this debilitating disease and may benefit from this treatment.
MediPharm Labs Corp.
MediPharm Labs continues to see significant growth opportunities ahead as numerous pharmaceutical, medical, wellness customers and brands continue to chose MediPharm as their preferred partner for turnkey GMP certified manufacturing and proven global supply chain distribution capabilities.
Additionally, the Acquisition provides immediate entry into the US market with a trusted and leading CBD health and wellness brand with an established manufacturing and distribution platform.
FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.
You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.